Results (3620)
EMA and the Heads of Medicines Agencies (HMA) have launched two public electronic catalogues: one for real-world data (RWD) sources and one for RWD studies.
NewsHumanData on medicines
Paxlovid: reminder of serious adverse reactions when taken together with certain immunosuppressants
NewsHumanCOVID-19MedicinesPharmacovigilanceReferrals
Following the launch in September 2022, EMA has accepted three academic and non-profit organisations developing advanced therapy medicinal products (ATMPs) into a pilot scheme, in which they benefit from enhanced support from the Agency.
NewsHumanAdvanced therapiesData on medicines
All ongoing clinical trials in the EU must be transitioned to the Clinical Trials Information System (CTIS) by 31 January 2025.
NewsHumanClinical trialsMedicines
EMA has just launched the new Antimicrobial Sales and Use (ASU) platform to support the collection of data by Member States on the sales and use of antimicrobials in animals.
NewsVeterinaryAntimicrobial resistance
EMA will harness its unique experience in coordinating intra-regional medicines regulation to support the strengthening of the African regulatory network.
NewsCorporate
On 24 January 2024, the CMDh endorsed precautionary measures recommended by EMA’s safety committee (PRAC) for the treatment of male patients with valproate medicines. These measures are to address a potential increased risk of neurodevelopmental disorders in children born to men treated with valproate during the 3 months before conception...
NewsHumanReferrals
On 25 January 2024, EMA’s human medicines committee (CHMP) endorsed the measures recommended by the Pharmacovigilance Risk Assessment Committee (PRAC) to minimise the risks of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) for medicines containing pseudoephedrine.
News
EMA’s human medicines committee (CHMP) recommended three medicines for approval at its January 2024 meeting.
NewsHumanMedicinesReferrals
Following re-examination, EMA’s human medicines committee (CHMP) has confirmed its initial recommendation to not renew the conditional marketing authorisation for Translarna (ataluren).
NewsHumanMedicines